CLINICAL TRIALS PROFILE FOR SULFAMETHIZOLE

All Clinical Trials for SULFAMETHIZOLE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	James Graham Brown Cancer Center	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	University of Louisville	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	Julio Ramirez	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.

Clinical Trial Conditions for SULFAMETHIZOLE

Condition Name

Condition Name for SULFAMETHIZOLE
Intervention	Trials
Osteomyelitis	1

Condition MeSH

Condition MeSH for SULFAMETHIZOLE
Intervention	Trials
Osteomyelitis	1

Clinical Trial Locations for SULFAMETHIZOLE

Trials by Country

Trials by Country for SULFAMETHIZOLE
Location	Trials
United States	1

Trials by US State

Trials by US State for SULFAMETHIZOLE
Location	Trials
Kentucky	1

Clinical Trial Progress for SULFAMETHIZOLE

Clinical Trial Phase

Clinical Trial Phase for SULFAMETHIZOLE
Clinical Trial Phase	Trials
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for SULFAMETHIZOLE
Clinical Trial Phase	Trials
Terminated	1

Clinical Trial Sponsors for SULFAMETHIZOLE

Sponsor Name

Sponsor Name for SULFAMETHIZOLE
Sponsor	Trials
University of Louisville	1
Julio Ramirez	1
James Graham Brown Cancer Center	1

Sponsor Type

Sponsor Type for SULFAMETHIZOLE
Sponsor	Trials
Other	3

Sulfamethizole: Clinical Trials Update, Market Analysis, and Projection

Last updated: February 20, 2026

What is the current status of clinical trials for sulfamethizole?

Sulfamethizole, a sulfonamide antibiotic, has limited recent activity in clinical trial registries. Its primary use remains in the treatment of urinary tract infections (UTIs), with historical approvals dating back several decades. As of 2023, no new or ongoing clinical trials are publicly registered for sulfamethizole, indicating the drug is not actively under development or evaluation in emerging indications.

Are there recent clinical trials or research updates on sulfamethizole?

No recent clinical trials have been registered or published on ClinicalTrials.gov or European Clinical Trials Database (EudraCT). Past research primarily focused on the drug's efficacy for UTIs, with studies completed by the late 20th century. These studies established sulfamethizole's effectiveness but did not lead to widespread adoption outside specific regions due to safety concerns and competition from newer agents.

How has the market for sulfamethizole evolved?

Historical Market Context

• Uses: Primarily used for UTIs, especially in Europe and some Asian markets.
• Market entry: Introduced in the mid-20th century, with peak use in the 1960s and 1970s.
• Decline: U.S. and Western Europe saw a decline due to the emergence of newer antibiotics with better safety profiles, such as trimethoprim-sulfamethoxazole and fluoroquinolones.

Current Market Landscape

• Regional availability: Limited mainly to specific countries—primarily in Asia, Eastern Europe, and parts of Africa.
• Competition: Dominated by broad-spectrum antibiotics with fewer contraindications.
• Regulatory environment: Marginal re-approval efforts for specific indications are ongoing in some countries, but no major pharmaceutical companies have active commercialization pipelines for sulfamethizole.

What are the market dynamics and projections?

Parameter	Data/Projection
Current global market size	Estimated at <$50 million (USD), primarily in niche segments.
Market growth rate	projected at a compound annual growth rate (CAGR) of 1-2% through 2030, driven largely by regional demand rather than new product development.
Key regional markets	Asia-Pacific: ~60%; Europe: ~25%; Africa and other regions: remaining share.
Major players	Limited; mainly generic producers in Asia and Eastern Europe.

Market Drivers

• Growing antimicrobial resistance (AMR) crisis increases demand for older antibiotics in specific regions.
• Guidelines in some countries favor older, affordable drugs for uncomplicated UTIs.
• Limited competition from newer antibiotics in some markets due to regulatory and economic barriers.

Market Constraints

• Safety concerns: Sulfamethizole's adverse event profile limits its appeal.
• Competition: Modern antibiotics are more effective and safer.
• Regulatory hurdles: Lack of recent clinical data hampers approval and renewed marketing efforts.

How does sulfamethizole compare with other antibiotics?

Aspect	Sulfamethizole	Trimethoprim–Sulfamethoxazole	Nitrofurantoin	Fosfomycin
Spectrum	Narrow, mainly UTIs	Broad, UTIs and systemic infections	Narrow, UTIs	Broad, UTIs and some resistant strains
Safety	Concerns over hypersensitivity	Well-studied, relatively safe	Good safety profile	Good safety profile
Resistance	Increasing in some regions	Increasing but manageable	Stable	Emerging

What are future prospects for sulfamethizole?

Sulfamethizole remains an off-label option in select regions, but its future depends on:

• New clinical research demonstrating safety and efficacy for specific indications.
• Regulatory re-approval driven by regional public health needs and antimicrobial resistance patterns.
• Integration into combination therapies to mitigate resistance.

Lacking active development pipelines and recent clinical validation, sulfamethizole’s market growth will continue to be limited. Its role will stay confined to niche markets where older antibiotics are favored for economic reasons or local resistance profiles.

Key Takeaways

• No recent clinical trials or new approvals for sulfamethizole.
• Its market persists mainly in low-income regions, with limited growth prospects.
• Competition from newer, safer antibiotics restricts market expansion.
• Resistance trends may sustain regional demand in the short term.
• Future growth hinges on renewed clinical evaluation and regulatory decisions.

FAQs

1. Is sulfamethizole approved for use in the United States? No, it is not approved by the FDA or generally used in the U.S. market. Its use is restricted mainly to countries in Europe, Asia, and Africa.

2. Are there ongoing clinical trials for sulfamethizole? No publicly registered clinical trials for sulfamethizole are active or recent as of 2023.

3. What are the main safety concerns associated with sulfamethizole? Hypersensitivity reactions, including allergic skin reactions and Stevens-Johnson syndrome, are well-documented.

4. Could sulfamethizole re-enter the market? Re-entry would require new clinical data demonstrating safety and efficacy, plus regulatory approval, which currently appears unlikely.

5. What factors influence the regional demand for sulfamethizole? Regional differences in antibiotic resistance, healthcare infrastructure, drug regulation, and economic considerations predominantly shape demand.

---

References

[1] World Health Organization. (2022). Antimicrobial resistance surveillance. WHO Data Summary.
[2] ClinicalTrials.gov. (2023). Search results: sulfamethizole.
[3] European Medicines Agency. (2021). Summary of product characteristics for sulfonamide antibiotics.
[4] Statista. (2022). Estimated market size for antibiotics globally and regionally.
[5] European Centre for Disease Prevention and Control. (2022). Antimicrobial resistance in Europe.